Claims for Patent: 8,119,116

Summary for Patent: 8,119,116

Title:	Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
Abstract:	The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention.
Inventor(s):	Ko; Young Hee (Owings Mills, MD), Geschwind; Jean-Francois (Potomac, MD), Pedersen; Peter L. (Columbia, MD)
Assignee:	John Hopkins University School of Medicine (Baltimore, MD)
Application Number:	12/355,115
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,119,116
Patent Claims:	1. A method of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate directly to the blood supply of the tumor in the subject via proximal catheterization. 2. The method of claim 1, further comprising administering a second chemotherapeutic agent. 3. The method of claim 2, wherein the second chemotherapeutic agent is selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2-chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin - dunomycin, dexamethosone, doxurubicin, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interfereon alfa n3, irinotecan, leucovorin calcium, leuprolide, levamisole, lomustine, megestrol, melphalan, L-sarcosylin, melphalan hydrochloride, MESNA, mechlorethamine, methotrexate, mitomycin, mitoxantrone, mercaptopurine, paclitaxel, plicamycin, prednisone, procarbazine, streptozocin, tamoxifen, 6-thioguanine, thiotepa, vinblastine, vincristine and vinorelbine tartrate. 4. The method of claim 1, wherein the tumor is located in a tissue selected from the group consisting of: brain, colon, urogenital, lung, renal, prostate, pancreas, liver, esophagus, stomach, hematopoietic, breast, thymus, testis, ovarian, skin, and uterine tissue. 5. The method of claim 1, further comprising administering a scavenger compound. 6. The method of claim 5, wherein the scavenger compound is selected from the group consisting of: lipoleic acid, glutathione and cysteine. 7. A method of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of a composition represented in general formula: ##STR00003## wherein, independently of each occurrence: X represents bromide; R.sub.1 represents OR, H, N(R'').sub.2, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, or C6-C12 heteroaryl; R'' represents H, C1-C6 alkyl, or C6-C12 aryl; R represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R'; and R' represents H, C1-C20 alkyl or C6-C12 aryl; wherein administration of the composition is administered directly to the blood supply of the tumor in the subject via proximal catheterization. 8. The method of claim 7, wherein the tumor is located in a tissue selected from the group consisting of brain, colon, urogenital, lung, renal, prostate, pancreas, liver, esophagus, stomach, hematopoietic, breast, thymus, testis, ovarian, skin, and uterine tissue. 9. The method of claim 7, further comprising administration of a scavenger compound. 10. The method of claim 9, wherein the scavenger compound is selected from the group consisting of: lipoleic acid, glutathione and cysteine. 11. The method of claim 7, further comprising administering a second chemotherapeutic agent. 12. The method of claim 11, wherein the second chemotherapeutic agent is selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2-chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin - dunomycin, dexamethosone, doxurubicin, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interfereon alfa n3, irinotecan, leucovorin calcium, leuprolide, levamisole, lomustine, megestrol, melphalan, L-sarcosylin, melphalan hydrochloride, MESNA, mechlorethamine, methotrexate, mitomycin, mitoxantrone, mercaptopurine, paclitaxel, plicamycin, prednisone, procarbazine, streptozocin, tamoxifen, 6-thioguanine, thiotepa, vinblastine, vincristine and vinorelbine tartrate.

Details for Patent 8,119,116

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2021-09-13